Top Markets
Coin of the day
Universal Vision Biotechnology Co., Ltd. Universal Vision Biotechnology Co., Ltd.

Universal Vision Biotechnology Co., Ltd.

3218
Rangering i aksjer #14904
Universal Vision Biotechnology Co., Ltd., established in 1992 and based in... Universal Vision Biotechnology Co., Ltd., established in 1992 and based in Taipei, Taiwan, manages a network of eye care clinics across both Taiwan and China. The company delivers a comprehensive range of ophthalmic services, encompassing advanced surgical interventions and treatments for various ocular conditions. Its surgical specialties include laser vision correction for common refractive errors such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related vision decline). They also perform intraocular lens procedures for presbyopia and cataracts, employing advanced techniques like phacoemulsification and femtosecond laser surgery. Beyond surgical solutions, Universal Vision addresses a wide spectrum of eye health concerns, offering services for myopia control, dry eye syndrome, retinal detachment, macular degeneration, strabismus (crossed eyes), amblyopia (lazy eye), and numerous other ophthalmic ailments. The company further provides a diverse array of vision products and optical aids, including various eyeglass frames, specialized multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, and both conventional and colored contact lenses. Nutritional eye supplements are also available. Additional offerings include oculoplastic and micro cosmetic eye surgery, alongside bespoke aesthetic medicine consultations. Furthermore, Universal Vision engages in optometric services, hospital administration, technical advisory roles, and the distribution and rental of medical equipment.
Aksjekurs
$4.55
Markedsverdi
$385.27M
Endring (1 dag)
-0.35%
Endring (1 år)
-21.53%
Land
TW
Handel Universal Vision Biotechnology Co., Ltd. (3218)

Kategori

P/E-forhold for Universal Vision Biotechnology Co., Ltd. (3218)
P/E-forhold per 2026 TTM: 0
Ifølge Universal Vision Biotechnology Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Universal Vision Biotechnology Co., Ltd. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.